June 2026 FDA Recall Drug by Boehringer Ingelheim Pharmaceuticals, Inc.
D-0657-2026 - CGMP Deviations

This Class II drug recall was voluntarily initiated by Boehringer Ingelheim Pharmaceuticals, Inc. on June 12, 2026 for the product Drug. The FDA reported the reason for recall as cgmp deviations. The product was distributed in OH and the recall is currently ongoing.

Recall Number: D-0657-2026

Reason for Recall
CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a different product.
Initiated
06-12-2026
Reported
07-08-2026
Quantity
560 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Boehringer Ingelheim Pharmaceuticals, Inc.
Synjardy XR Tablets (empagliflozin and metformin hydrochloride extended-release tablets), 12.5/1000 mg, 60 Tablets per Bottle, Rx only, Distributed by: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT 06877 USA. NDC: 00597-0300-45

Batch or Lot Expiration Information

Lot# Lot 3244413; Exp. 12/31/2028